The total return over the past 12 months is +26.11% vs. +16.94% for the S&P 500. So far it's up -13.40% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +26.11% | +78.37% | (0.28%) | N/A | N/A | N/A |
| Total Return CAGR | +26.11% | +78.37% | (0.28%) | N/A | N/A | N/A |
| Revenue CAGR | +76.11% | +241.34% | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Arcutis Biotherapeutics, Inc. (ARQT)
| Year | Start price | End price | ARQT Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $29.04 | $25.15 | (13.40%) | +14.51% | (27.91%) |
| 2025 | $13.93 | $29.04 | +108.47% | +17.72% | +90.75% |
| 2024 | $3.23 | $13.93 | +331.27% | +24.89% | +306.38% |
| 2023 | $14.80 | $3.23 | (78.18%) | +26.19% | (104.37%) |
| 2022 | $20.74 | $14.80 | (28.64%) | (18.17%) | (10.47%) |
| 2021 | $28.13 | $20.74 | (26.27%) | +28.74% | (55.01%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
